Methods: Small molecular chemical compounds against FIR and FIRΔexon2 were screened among 2,3275 chemicals by natural product depository array (RIKEN, Wako, Saitama, Japan).
INTRODUCTION
C-Myc is overexpressed in the majority of colorectal cancers and is required for tumor maintenance [1, 2] . The far upstream element (FUSE) is a sequence required for proper expression of the human c-Myc gene. The FUSE is located 1.5 kb upstream of c-Myc promoter P1, and binds the FUSE binding protein1 (FUBP1), a transcription factor stimulating c-Myc expression in a FUSE dependent manner [3, 4] . FUBP1 is overexpressed and regulates proliferation and migration of hepatoma cells [5] [6] [7] . Yeast two-hybrid analysis revealed that FUBP1 binds to a protein that has transcriptional inhibitory activity termed the FUBP1-interacting repressor (FIR), and FIR was found to engage the transcriptional factor IIH [TFIIH/p89/xeroderma pigmentosum type B (XPB)] helicase and repress c-Myc transcription [8] . FIR induces apoptosis via c-Myc suppression, and is thus a suitable cancer therapy [9, 10] . Adenovirus-FIR or Sendai virus-FIR vectors gene therapy for nasopharyngeal cancer were reported [11] [12] [13] [14] . Up to 60% of all human genes present at least one alternative splice variant [15] . Disturbed alternative splicing (AS) in cancer cells or hepatitis B virus (HBV) virus affect host's immune response [16, 17] . AS has been documented to play a significant role in human disease and DNA repair in cancers [18] [19] [20] [21] . A splicing variant of FIR that lacks exon2, FIRΔexon2, failed to repress c-Myc and inhibited FIR-induced apoptosis suggesting FIRΔexon2 is a dominant negative of FIR in human cancers [22] . On the other hand, FIR is a splicing variant form of poly(U)-binding-splicing factor (PUF60) [23, 24] . Anti-PUF60 autoantibodies are reported to be detected in the sera of autoimmune diseases such as dermatomyositis, Sjogren's syndrome or idiopathic inflammatory myopathy [25, 26] . Further, the combination of anti-FIRs antibodies with other clinically available tumor markers such as anti-p53 antibodies, CEA, and CA19-9 further improved the specificity and accuracy of diagnosis [27, 28] . Besides, haploinsufficiency of FIR mouse model promoted p53-dependent T-cell acute lymphoblastic leukemia progression [29] . SAP155, a subunit of the essential splicing factor 3B (SF3B) subcomplex in the spliceosome, is required for proper P27Kip1 pre-mRNA splicing, and P27Kip1 arrests cells at G1 [30, 31] . Moreover, spliceostatin A (SSA) or pladienolide, a natural SF3B inhibitor, markedly inhibited P27 expression by disrupting its pre-mRNA splicing with striking cell killing effects [32, 33] . Further, FIR/PUF60 is required for transcriptional and post-transcriptional regulation of HBV pgRNA expression [34] . To develop novel diagnosis and therapy for hepatoma targeting FIR (PUF60)/FIRΔexon2, small molecular chemical compounds against FIRΔexon2 were screened among 2,3275 chemicals by natural product depository (NPDepo) array at RIKEN (Japan) to develop anti-cancer drugs [35] [36] [37] . Finally, small inhibitory chemicals against FIR/FIRΔexon2 for hepatoma therapy will be discussed.
METHODS

Cancer cell lines
Human cervical SCCs (HeLa cells), gastric cancer cells (NUGC4), HLE cells and HLF cells were purchased from the American Type Culture Collection (https://www.atcc.org/). These cells were treated as described previously [18] . All cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum (FCS; Invitrogen, Tokyo, Japan) and 1% penicillin-streptomycin, and they were cultured at 37 °C in a humidified atmosphere containing 5% CO 2 .
Protein extraction, western blotting and antibodies
Culture medium was removed, and the cells were washed twice with cold (4 °C) phosphate buffered saline (PBS), lysed with 1:20 β-mercaptoethanol and 2x sample buffer, and incubated at 100 °C for 5-min. Whole-cell lysates were assayed for protein content (Bio-Rad, Hercules, CA, USA), and 10 μg of proteins were separated by sodium dodecyl sulfate -poly-acrylamide gel electrophoresis on 7.5% or 10%-20% XV PANTERA gels and transferred onto polyvinylidene fluoride membranes using a tank transfer apparatus. The membranes were blocked with 0.5% skim milk in PBS overnight at 4 °C. Antigens on the membranes were detected with enhanced chemiluminescence detection reagents (GE Healthcare UK Ltd., Buckinghamshire, UK). Membranes were incubated with primary antibodies [Supplementary Table 1] for 1 h at room temperature, followed by three 10-min washes with 1xPBS/0.01% Tween 20. Membranes were then incubated with commercial secondary antibodies [Supplementary Table 1] , followed by three 15-min washes with 1xPBS/0.01% Tween 20. The primary mouse monoclonal antibody against FIR's C-terminus (6B4) was described previously [22] .
Small molecular chemical compounds screening against FIRΔexon2
Small molecular chemical compounds against His-tagged FIR (His-FIR) and His-tagged FIRΔexon2 were screened among 2,3275 chemicals of NPDepo at RIKEN as described previously [35] [36] [37] . Briefly, His-FIR (645 μg/mL) and FIRΔexon2 (652 μg/mL) proteins were applied to NPDepo array that contains 2,3275 natural chemical compounds. FIRΔexon2 inhibitor BK697 was diluted in dimethyl sulfoxide (DMSO) at the concentration of 10 mm, stored in room temperature, treated into HeLa and NUGC4 cell lines with different concentrations at different time intervals (see details in figure legends). Briefly, on day one, NUGC4 cells or HeLa cells were prepared in Iscove's modified Dulbecco's medium supplemented with 10% FBS. On day two, candidate chemicals that inhibit FIRΔexon2 protein were diluted in DMSO at the concentration of 10 mm and added as 10 L or 20 L/well/2 mL in the medium (final concentration in medium was 50 mol/L and 100 mol/L respectively) or added as 20 L or 60 L/well/2 mL medium (final concentration in medium was 100 mol/L and 300 mol/L respectively). 100 mol/L or 300 mol/L of BK697 was treated to NUGC4 cells for 24 h, 50 mol/L or 100 mol/L of BK697 was treated to NUGC4 cells or HeLa cells for 6 h, 24 h and 48 h at 37 °C in a CO 2 incubator.
Screening procedures of natural small molecular weight chemical compounds that potentially bind to FIR/FIRΔexon2
Small molecular weight chemical compounds potentially bound to FIRΔexon2 were previously identified [ Figure 1 ] from the NPDepo at RIKEN, which were a collection of the isolates from natural products, build by Dr Hiroyuki Osada (RIKEN, Japan) and his coworkers [35] [36] [37] .
Procedure of in silico screening
In the process for searching potent compounds, in silico screening was performed from the commercial chemical database. First, 1000 compounds were selected from the Namiki database that contains 5 million chemical entries, from the viewpoint of structural similarity to natural product that was identified to be bound to FIR in our previous work. Second, 125 compounds were extracted from the selected 1000 chemicals in terms of the electrostatic potential caused by the distribution of positive and negative charges. Finally, 5 compounds were purchased from a supplier for experimental assay. Namiki database (Namiki Shoji Co., Ltd., Tokyo, Japan, https://www.namiki-s.co.jp/english/) was a collection of commercially available screening-candidate chemicals.
Display of three-dimensional structure of F-box and WD repeat domain-containing 7 (FBW7)
To examine the possibility of molecular interaction between FBW7 and FIRs from structural viewpoint, two crystal structures were downloaded from protein data bank (PDB , https://www.rcsb.org/). One is a complex structure of FBW7 (PDB entry code: 2OVR). The other is the structure of an U2AF homology motif (UHM) domain in complex with UHM-ligand motif (ULM) of SAP155 (PDB entry code: 2PEH). Both crystal structures were visualized by PyMOL (DeLano, W. L.; The PyMOL Molecular Graphics System, Schrödinger, LLC).
MTS assay (Cell proliferation assay)
One day before the chemical treatment, cells were cultured in 100 μL medium in flat-bottomed 96-well plates so that the cells will reach 40%-80% confluent at the time of chemical treatment. After 24 h incubation at 37 °C/5% CO 2 , cells were treated with chemicals. After 24 h incubation at 37 °C, CellTiter 96® AQueous One Solution Reagent (Promega, Madison, WI, USA) was added to each well according to the manufacturer's instructions. Briefly, CellTiter 96® AQueous One Solution Reagent was warmed up and added to each well (20 L/well), incubated for 1 h at 37 °C. Then, 10% SDS solution was added to each well (25 L/well). Cell viability was determined by measuring the absorbance at 490 nm using a 550 Bio-Rad plate reader. All samples are tested in duplicate, absorbencies were tested 3 times. Same volume of DMSO was used as negative control. Same volume of 3% H 2 O 2 was used as positive control.
IUPAC name
Structure His-FIR His-FIRΔexon2
1,4a-Dimethyl-2,3,4,4a,9,9a-hexahydro-1H-fluorene-1,9-dicarboxylic acid 3+ 
RESULTS
Mechanism in carcinogenesis of FIR/FIRΔexon2/PUF60 as a target for cancer diagnosis and therapy
Previous studies revealed that FUBP1, FIR (PUF60)/FIRΔexon2, SAP155, and SAP130 were over expressed in hepatocellular carcinoma (HCC) tissue [18] . Additionally, FIR/FIRΔexon2 mRNA levels were increased in HCC [38] . Recent studies have been revealed regarding direct protein interactions between UHM family and ULM family [ Supplementary Figure 1] [39 -41] . SAP155/SAP145/SAP130 subunits consist of SF3B complex and UHM of FIR/ PUF60 directly binds to ULM of SAP155 (SF3B1) [Supplementary Figure 1A-C] [32, 41, 42] . Further, FUBP1, FIR (PUF60)/FIRΔexon2, SAP155, and SAP130 were over expressed in hepatitis C virus (HCV)-related HCC tissue and FIR (PUF60)/FIRΔexon2 reflects DNA damage [Supplementary Figure 1D] [18]
. Bleomycin-induced DNA damage decreased SAP155 and significantly increased FIR/FIRΔexon2 mRNA expression as well as the FIRΔexon2: FIR ratio in hepatoblastoma (HLE and HLF) cells [18] . Therefore, FUBP1/FIR (PUF60)/FIRΔexon2 proteins, mRNAs and/or autoantibodies against these peptides are highly possible biomarker candidates for hepatoma diagnosis. Anti-FIR/FIRΔexon2 autoantibodies were detected in several gastrointestinal cancers [27, 28] . Anti-FIR/FIRΔexon2 autoantibodies in the sera of HCC patients are now under investigation. Given FIRΔexon2 is a dominant negative regulator of FIR/PUF60, FIRΔexon2 inhibition is an advantageous target for cell growth suppression [ Figure 2A ]. Inhibition of SF3B (SAP155) by siRNA or SSA resulted in c-Myc overexpression possibly due to the FIR downregulation [ Figure 2B ]
. Knockdown of SAP155 or FIR was used to investigate their reciprocal influence on each other and on c-Myc transcription, pre-mRNA splicing, and protein expression [31] . FIR and FIRΔexon2 were co-immunoprecipitated with SAP155 [31] . UHM of FIR/PUF60 at carboxyl-terminus directly binds to W (Typ) D (Asp)-domain of SF3B1 (SAP155) as ULM [42, 43] . The tight FIR/FIRΔexon2-SAP155 interaction disables established FIR and SAP155 functions disturbing the synthesis of normally spliced FIR mRNA. FIRΔexon2 potently forms a heterodimer with FIR and thus FIRΔexon2 interferes with FIR to bind to FUSE [Supplementary Figure 1D] . These results strongly suggest that FIRΔexon2 antagonized FIR in c-Myc transcriptional suppression and simultaneously interferes with SF3B in splicing during tumor progression. Therefore, both common and discriminating recognition elements in the UHM-ULM binding interface provide a rationale for a structural basis for specific UHM-ULM interactions and a platform of intermolecular interactions governing disease-related AS in eukaryotic cells [40] . For instance, SF3B1 (SAP155)/FIR/PUF60 complex is a target of cancer therapy. In these scenarios, low molecular weight artificial chemical, BK697, was synthesized by in silico screening that targets FIRΔexon2 in this study [ Figure 2B ]. Small molecular chemical compounds against FIRΔexon2 were screened among 23,275 chemicals of NPDepo by Dr Hiroyuki Osada and his colleagues (RIKEN, Wako, Saitama, Japan) to develop cancer therapy [ Figure 1 ]. Nine small molecular chemicals were identified by NPDepo screening against FIR and four chemicals against FIRΔexon2 as candidates of interacting chemicals [ Figure 1 ].
The interaction of FIRΔexon2 and WD-like domain of FBW7 and in silico screening of small molecular chemical compounds against FIR/FIRΔexon2 for cancer therapy FBW7 frequently is mutated in hematopoietic tumors [44] . FBW7 is a member of the Skp1-Cull-F-box type ubiquitin ligase complex and is involved in degradation of various growth-related proteins, Notch1, c-Myc, c-Jun, and cyclin E via the proteasome system [44] , indicating FBW7 is a tumor suppressor in cancer development and progression [45] . Remarkably, three-dimensional structure analysis revealed the hypothetical inhibitory mechanism of FBW7 function by FIR/FIRΔexon2 [ Figure 3 ]. The binding structure between SAP155 (SF3B1) and one of the splicing factors containing UHM, SPF45, was already clarified by X-ray crystal analysis (PDB code: #2PEH) [ Figure 3A and B]. In the 2PEH structure, the crystal unit cell contains two SPF45 recombinant proteins (a.a. 301-401) and two SAP155 partial peptides (a.a. 333-342). SPF45 has an amino sequence of LNGRYFGGRVVKA [ Figure 3A ] and similar sequences are commonly seen at the C-terminal domains of FIR and U2AF65 [ Figure 3B ]. According to the crystal structure, 2PEH, SPF45 makes a strong interaction with a WD part of SAP155 at the domain of the above-mentioned conserved sequence. The binding structure between splicing factor 3B (SF3B) and one of the splicing factors containing U2AF homology motif, SPF45, was already clarified by X-ray crystal analysis (protein data base code: #2PEH). In the 2PEH structure, the crystal unit cell contains two SPF45 recombinant proteins (a.a. 301-401) and two SF3B partial peptides (a.a. 333-342); (B) SPF45 has an amino sequence of LNGRYFGGRVVKA and similar sequences are commonly seen at the C-terminal domains of far upstream element-binding proteininteracting repressor (FIR) and U2AF65. According to the crystal structure, 2PEH, SPF45 makes a strong interaction with a WD part of SF3B at the domain of the above-mentioned conserved sequence. FIR and U2AF65 are also expected to interact with SF3B through the domains with the similar amino sequences; (C) F-box and WD repeat domain-containing 7 (FBW7) has many WD motifs and most of the motifs are involved in the conformational stabilization of the WD-repeated domain. Although those WD motifs are not related to the ligand recognition of FBW7, there is an extra pair of W425 and D399 at the center of the WD-repeated domain. Most of the ligands of FBW7 are the amino peptides that include phosphorylated Thr or Ser, because three Arg residues are located at the center of the WDrepeated domain and hold the negatively charged peptides by phosphorylation. The extra pair of W and D at the WD-repeated domain will not be involved in the ligand recognition of the phosphorylated peptides, but the WD pair can interact with the peptide with the above-mentioned conserved sequence from the structural viewpoint. Hence, FIR may be bound to the WD-repeated domain and block the function of FBW7. FIR: FUBP1-interacting repressor; WD: W (Typ) D (Asp)
A B C FIR and U2AF65 are also expected to interact with SAP155 through the domains with the similar amino sequences. FBW7 has many WD motifs and most of the motifs are involved in the conformational stabilization of the WD-repeated domain. Although those WD motifs are not related to the ligand recognition of FBW7, there is an extra pair of W425 and D399 at the center of the WD-repeated domain. Most of the ligands of FBW7 are the amino peptides that include phosphorylated Thr or Ser, because three Arg residues are located at the center of the WD-repeated domain and hold the negatively charged peptides by phosphorylation [ Figure 3C ]. The extra pair of W and D at the WD-repeated domain will not be involved in the ligand recognition of the phosphorylated peptides, but the WD pair can interact with the peptide with the above-mentioned conserved sequence from the structural viewpoint. Hence, FIR may be bound to the WD-repeated domain and block the function of FBW7 [ Figure 3C ]. Together, latent disturbance of FBW7 by FIR/FIRΔexon2/PUF60 in cancers inhibit degradation of substrate proteins.
FBW7 expression was decreased significantly in esophageal squamous cell carcinoma (ESCC) [46] . Conversely, FIR and FIRΔexon2 were overexpressed in ESCC. Especially, the knockdown of SAP155 (SF3B1), a splicing factor required for proper AS of FIR pre-mRNA, decreased cyclin E [46] . Therefore, disturbed AS of FIR generated FIR/FIRΔexon2 with cyclin E overexpression in esophageal cancers, indicating that SAP155 siRNA potentially rescued FBW7 function by reducing expression of FIR and/or FIRΔexon2 [46] . A novel low molecular weight chemical, BK697, with WD-like domain structure that inhibits FIR/FIRΔexon2 [ Figures 2B and 3] [46]
, indicating simultaneous downregulation of FBW7 and E-cadherin accompanied with disturbed splicing of FIR is required for migration [or epithelial-mesenchymal transition (EMT)] in cancers.
Cell growth inhibition by in silico-screened compounds against FIRΔexon2 protein
A small molecular weight chemical that has WD-like motif was identified by NPDepo screening [ Figure 1 -top, Figure 4 -(A), (C)]. From computer screening to search synthesized chemicals that mimicking the structure of the identified compound using Namiki database (Namiki Shoji Co., Ltd., Tokyo, Japan) that was composed of commercially available chemicals [ Figure 4- . Synthesized compounds were intended to inhibit FIRΔexon2 protein function.
Low molecular weight artificial chemical, BK697, that inhibits FIRΔexon2 protein function suppressed tumor cell growth
Affiliated small molecular weight chemicals that have WD-like motif screened by NPDepo [ Figure 5A , square]. Based on the computer screening, lots of similar chemicals were designed and seven compounds were selected for treating with HLE and HLF cells to examine cell growth inhibition [ Figure 5A , arrows]. Expectedly, BK697 effectively suppressed hepatoblastoma cells, HLE and HLF cells [ Figure 5B ]. BK697 suppressed FIR/FIRΔexon2 expression on dose-dependent manner in NUGC4 cells [ Figure 5C , left] and HeLa cells [ Figure 5C , right]. Particularly, FIR/PUF60 is required for HBV cccDNA replication [34] , BK697 is a promising candidate for hepatoma treatment by suppressing HBV cccDNA. Previously, FIR has been revealed to contribute to the splicing of PKM1 to PKM2 in mice thymic lymphoma using six-plex tandem mass tag quantitative proteomic analysis in mice model [ . SAP155 (SF3B1) and FIR/PUF60 are required for E-cadherin expression through engaging in its mRNA editing that is pivotal for cell-cell adhesion or EMT [52] . Together, BK697 suppressed cell growth through interfering FIRΔexon2 with binding to analogues of WD-like motif of FBW7 in the degron pocket (W425 D399 in the 3D-structure) [ Figure 3 ]. Together, simultaneous downregulation of FBW7 and E-cadherin is potentially pivotal for invasion or metastasis of cancers through EMT and may also contribute to therapeutic target for cancers. Clinically, BK697 and its derivatives are potential candidate anticancer drugs for cancers targeting FBW7 and E-cadherin suppression.
DISCUSSION
This study demonstrated that FIR strongly repressed endogenous c-Myc transcription and induced apoptosis. Most importantly, a splicing variant of FIR, FIRΔexon2, found frequently in human primary colorectal cancer tissue, not only lacked the c-Myc-suppressing and apoptosis-inducing action of FIR, but prevented normal FIR from performing these activities. Thus FIRΔexon2 may contribute to tumor progression by enabling higher levels of c-Myc expression and greater resistance to apoptosis in tumors than in normal cell [ Figure 2A ]. The value of FIR and/or FIRΔexon2 detection for cancer diagnosis is under investigation. Recently, PUF60, another FIR splicing variant having exon 5, directly binds to splicing factor SF3B1 with UHM [39] and inhibition of SF3B (SAP155 is a subunit of SF3B) by natural chemicals demonstrated strong antitumor effect [ Figure 2B ] [32, 33] . Hypoxia leads to AS of FIR/PUF60 and in PC3 prostate cancer cells [53] . Given the central role of c-Myc in the development of many cancers, and inhibition of splicing function of PUF60 (or FIR itself) with SF3B indicates strong antitumor activity, one route to the development of DNA damage/cell cycle [18] [19] [20] [29] [30] [31] 46] T-cell type acute lymphoblastic leukemia [43, 50] SAP155(SF3B1)-FIR(PUF60) interaction in alternative splicing of mRNAs [23, 29, 31, [40] [41] [42] F-box and WD repeat domain-containing 7 (FBW7)/proteosome [44, 45] autoandibodies/immune reaction [21, 24, 25, 27, 28] Alternative splicing of mRNAs [17] [18] [19] [21] [22] [23] [24] 33, 34] E-caherin/invasion/metastasis, Epithelial mesenchymal transition (EMT) [52] carcinobgenesis [5, 6, 56, 57] (FUBP1), [9, 38, 43] (FIRΔexon2) tolerance for hypoxia [53] 2 Hepatoma proliferation, migration, cancer metabolism, signal transduction, [6, 18, 38, 51, 56, 57] 3 Hepatitis B virus (HBV)/ hepatitis C virus (HCV) covalantly closed circular DNA (cccDNA of HCV) [34] ENI/ENII enhancer region [34] HBV core promotor [34] spliced RNA (HBV RNA) [17] HCV [55] 4 Rare disease CHARGE syndrome [59] Phenotypic variability of genetic diseases [59] Verheji syndrome [59, 60] developmental delay, intelllectual disability, microcephaly, craniofacial, renal and cardiac defects [58, 59] Eye coloboma and complex cardiac malformations [59, 61] atrioventricular septal defect and hypoplastic aortic arch, facial dysmorphism, microretrognathia, dysmorphic ears, clinodactyly of the 5th digit on both hands, mild rocker bottom feet and abnormal third sacral vertebra [61, 62] microcephaly, short stature, intellectual disability, and heart defects with a de novo c.505C > T variant leading to a p.His169Tyr change in PUF60. (PUF60 deficiency) [63] [64] [65] A B MTS Assay (Cell confluency was 80% at time of drug treatment)
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B l a n k ( u n t r e a t e d ) N e g a t i v e B K -6 9 6 B K -6 9 7 B K -6 9 7 B K -6 9 8 B K -6 9 8 B K -6 9 9 B K -6 9 9 B K -6 7 0 B K - From computer screening to search synthesized chemicals that mimicking the structure of the identified compound using Namiki database (Namiki Shoji Co., Ltd., Tokyo, Japan) that was composed of commercially available chemicals after natural product depository array at RIKEN (Japan). Affiliated chemicals were screened and indicated in the square (square). Based on the computer screening, lots of similar chemicals were designed and seven compounds were selected for treating with HLE and HLF cells to examine cell growth inhibition ( . As for Ad-FIR or Sendai virus-FIR vector, the transduction efficiency showed that the efficacy in preclinical trials and combination treatment with standard chemoradiation and Ad-FIR/Sendai-FIR gene therapy may be an attractive modality in the future [10] [11] [12] [13] [14] . HBV has a small (3.2 kb), partially-double stranded, relaxed-circular DNA genome that encodes four overlapping open reading frames (ORFs) [54] . The genomic transcripts from these overlapping four ORFs act mRNAs for precore, core and polymerase. The genomic transcript that encodes both core and polymerase is multifunctional and referred to as pgRNA [54] . The core protein binds to HBV covalently closed circular DNA (cccDNA). The cccDNA forms a minichromosome in the nucleus of the hepatocyte [54] . Recent nucleoside analogues and interferons treatment for HBV-positive patients do not achieve complete clearance of viral genome cccDNA in the nucleus [ Figure 6 ]. To our interest, PUF60 was identified as a versatile regulator of transcriptional and post-transcriptional steps in expression of HBV 3.5 kb, precore plus pgRNA [34] . This is the first to identify a host cell factor (protein) involved in not only positively regulating viral gene expression but also negative regulation of the same viral life cycle [34] . Therefore, FIR/PUF60 is also a novel promising target to inhibit HBV cccDNA transcription as well as interfering FBW7 function [ Figure 6 ]. Given the FIR/ PUF60 is required for HBV cccDNA replication [34] and novel small molecular weight chemicals including BK697 that suppresses FIR/PUF60 expression [ Figure 5C ], those chemicals have advantage to eliminate HBV cccDNA than other strategies as recent nucleoside analogues and interferons treatment. Further, the amino terminus of FIR was necessary to repress transcription from the c-Myc promoter by suppressing FUBP1, FUBP [ Figures 2 and 6] [22 ] . FUBP1/FIR(PUF60)/TFIIH system FIR suppresses endogenous c-Myc at transcriptional level by its amino terminal domain [ Figure 2A ]. Further, FUBP1 facilitates persistence HCV replication in HCC cells [55] . FUBP1 as well as FIR (PUF60) is required for tumor growth in HCC [38, 56, 57] . Additionally, FUBP1/FIR (PUF60)/TFIIH complex potentially support the growth of hepatoma by c-Myc gene transcriptional activation and HCV replication [ Table 1 ]. Further, FUBP1/FIR/FIRΔexon2/PUF60 are expressed in HCC tissue and less expressed in the normal tissue in developed cells [18, 38] . Therefore, small molecular weight chemicals targeting FUBP1/FIR/FIRΔexon2/PUF60 system are expected to be harmless.
Recently, FIR/PUF60 and human rare disease are reported [ Table 1 ]. CHARGE syndrome shows an autosomaldominant, multiple congenital anomaly symptom characterized by vision and hearing loss, congenital heart disease, and malformations of craniofacial and others [58] . Pathogenic variants in CHD7 of CHARGE syndrome patients were present in 15 of 28 individuals (53.6%), whereas 4 (14.3%) individuals had other pathogenic variants such as RERE, KMT2D, EP300, or FIR/PUF60 [59] . A two base pair deletion was identified in the PUF60 gene, which is one of three genes in the critical region of the 8q24.3 microdeletion syndrome (Verheij syndrome) that shows intellectual disability [60] . In 2013, patients with microdeletions of chromosome 8q24.3 including FIR/PUF60 were found to have developmental delay, microcephaly, craniofacial, renal and cardiac defects were found in six patients with variants in FIR/PUF60 [61] . Eye coloboma and complex cardiac malformations belong to the clinical spectrum of PUF60 variants [62, 63] . The fetus presented atrioventricular septal defect and hypoplastic aortic arch, facial dysmorphism, microretrognathia, dysmorphic ears, clinodactyly of the 5th digit on both hands, mild rocker bottom feet and abnormal third sacral vertebra [64] . An individual was reported with microcephaly, short stature, intellectual disability, and heart defects with a de novo c.505C > T variant leading to a p.His169Tyr change in PUF60 [65] . The publications that show the direct interaction between FIR/PUF60 deficiency and human disease have been accumulating [ Table 1 ]. FIR/PUF60 deficiency-associated amino-acid substitutions, even within a single RNA recognition motif, altered selection of competing 3' splice sites (3'ss) and branch points of a FIR/PUF60-dependent exon and the 3'ss choice was also influenced by AS of FIR/PUF60 [65] . FIR/FIRΔexon2/PUF60 is a promising target to the development of cancer diagnosis and therapies directed HBV, HCV, FBW7 as well as c-Myc. Together, FIR/PUF60/FIRΔexon2 are multifunctional through AS and applicable for clinical use for HBV suppression especially for hepatoma treatment.
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